Spiracur, Inc. announced important results from a clinical study highlighting the efficacy of its SNaP Wound Care System for the treatment of chronic lower extremity wounds. The data was presented this week at the Fall 2010 Symposium on Advanced Wound Care (SAWC). The 12-center, 65-patient randomized controlled trial compared negative pressure wound therapy (NPWT) between the KCI Wound V.A.C. Therapy System and the SNaP Wound Care System for the treatment of chronic lower extremity wounds.

Read the full story here

Derma Sciences, Inc. has announced that patient screening in its DSC127 Phase 2 trial in diabetic foot ulcer healing will be completed tomorrow, and that enrollment in the trial will conclude on September 30. This randomized, double-blind, placebo controlled study of up to 75 patients will look at the percentage of diabetic ulcers completely healed over a 12-week period, among other outcomes.

Read the full story here

Millions of Americans seek relief from the signs of an aging complexion, which includes fine lines, wrinkles, enlarged pores, age spots, sun spots and uneven skin tone and texture. Laser Clinique has announced TotalFX fractional laser resurfacing technique. This procedure is the latest treatment for painlessly and efficiently eliminating the signs of aging. For today’s more active population, the prolonged healing time involved with conventional laser or face-lift surgery is not appropriate.

Read the full story here

A new study from the Queensland Institute of Medical Research (QIMR) has found that the major component of clove oil may be a promising lead as a new topical treatment for scabies. Plant essential oils have long been studied for their effects against mites, ticks, lice and mosquitoes. Researchers tested the clove oil and nutmeg oil on two different types of mites in the laboratory to see how many died from contact with the oils.

Read the full story here

BioAlliance Pharma SA announced the grant of a European patent protecting its product acyclovir Lauriad®. This patent is now validated in all European countries; this first patent validation is a major step and the procedures up to the grant are ongoing in the other major global areas, America and Asia. This patent specifically protects the muco-adhesive tablet containing acyclovir, its process for manufacturing and its clinical application.

Read the full story here

Medicis announced that FDA has approved additional strengths of SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. The Company believes all forms of SOLODYN currently approved for use are covered by its patent rights.

Read the full story here

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with LytixarTM (LTX-109) treatment of skin infections caused by Gram positive bacteria. Preclinical models have demonstrated that LytixarTM is strongly bactericidal, being equally effective against wild-type as well as drug-resistant bacteria such as MRSA. Because of its unique membrane-lysing mechanism of action, there is no cross-resistance to other drugs.

Read the full story here

Cascade Technologies, Inc. announced that its wholly-owned subsidiary Spectral Molecular Imaging, Inc. will complete development of its new product SkinSpect™, aimed at early detection of melanoma by hyperspectral imaging, in mid-September 2010. The device incorporates new advances in component technologies, as well as experience derived from previous prototypes developed under federal funding and tested in the clinic. The spectral range covered is also extended, now ranging from 385 nm to 920 nm.

Read the full story here

The FDA is warning consumers about the risk of ultraviolet radiation overdose with the Tootsie Tanner portable foot tanning device. Use of the tanning device can lead to an overdose of ultraviolet radiation because its labeling recommends an improper duration of exposure to radiation and the device has an inadequate timer. The labeled exposure schedule indicates that the device may be used for 30 minutes, and the timer control permits 30 minutes exposure.

Read the full story here

Xenon Pharmaceuticals Inc. announced that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN. XEN402 has been developed by Xenon as a topical ointment formulation and recently concluded a 21-day cumulative dose safety tolerability phase 1 study in normal human volunteers. The product was well tolerated and achieved good drug concentrations in the skin.

Read the full story here